UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Biologic therapies for systemic lupus erythematosus: where are we now?

Murphy, G; Isenberg, DA; (2020) Biologic therapies for systemic lupus erythematosus: where are we now? Current Opinion in Rheumatology , 32 (6) pp. 597-608. 10.1097/BOR.0000000000000736. Green open access

[thumbnail of Isenberg_Biologic Therapies for SLE 11.6.2020.pdf]
Preview
Text
Isenberg_Biologic Therapies for SLE 11.6.2020.pdf - Accepted Version

Download (441kB) | Preview

Abstract

PURPOSE OF REVIEW: Conventional approaches using hydroxychloroquine, corticosteroids and immunosuppressives have improved the prognosis for systemic lupus erythematosus (SLE) patients. Unfortunately, they have reached the limits of what they can achieve and patients still die prematurely and/or find their quality of life greatly impaired. Here, we discuss the problems of assessing activity in SLE, optimizing clinical trial design and more recent biologic approaches. RECENT FINDINGS: The success of B-cell depletion using Rituximab in open clinical studies, the approval of Belimumab (blocks the B-cell activating factor BAFF) and improvements in clinical trial design, gives cause for hope. Approaches including the use of fully humanized anti-CD20 and CD19 monoclonals, blocking interferons, inhibiting Bruton's tyrosine kinase (BTK), blocking the CD40 ligand (CD40L), utilizing an analogue of the FcɣRIIB and an IL12-23 blocker and targeting the JAK-STAT pathway have met end points in phase II and III trials. SUMMARY: For 20 years, we hoped that the successes of the biologic therapies in rheumatoid arthritis and psoriatic arthritis would be replicated in SLE but we have been generally disappointed. However, the encouraging recent results with monoclonals that block interferon and fully humanized anti-CD20 in particular, offer the prospect of a real revolution in the treatment of SLE.

Type: Article
Title: Biologic therapies for systemic lupus erythematosus: where are we now?
Open access status: An open access version is available from UCL Discovery
DOI: 10.1097/BOR.0000000000000736
Publisher version: http://doi.org/10.1097/BOR.0000000000000736
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10136536
Downloads since deposit
51Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item